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AN ASSESSMENT OF PAKISTANI PHARMACY AND MEDICAL 
STUDENTS’ KNOWLEDGE OF BLACK BOX WARNINGS
G. Murtaza1, S.A. Khan1, G. Murtaza (Junior)1, K. Javed1, F. Akram1, A.A. Hamid1, I. Hussain1
Abstract: Food and Drug Administration delivers the black box warnings (BBW) which should appear on the leaflets of medi-
cines for patient awareness and the prescription of drugs indicating its highly fatal adverse effects to human body. The aim of 
this study was to assess the knowledge of Pakistani pharmacy and medical students about BBW. A questionnaire containing 
contents about BBW was given to the 1st, 2nd and 3rd professional year pharmacy and medical students from different phar-
macy and medical institutes. A 76% survey response rate was observed. It was observed that student’s knowledge about BBW 
improves in association with the promotion in professional years of pharmacy and medical education. The results indicate that 
student’s knowledge about black box increases with the study level. Training in black box warnings should be implemented 
in pharmacy and medical institutions influencing the meaningful ways to educate and train pharmacy and medical students, 
and help these students to get recent knowledge about black box warnings so that, in future, they may perform an ethical 
practice in their respective fields.
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Una evaluación del conocimiento de estudiantes de medicina y de farmacia en Pakistán sobre 
alertas de medicamentos
Resumen: La Agencia Reguladora de Alimentos y Medicamentos comunica alertas sobre medicamentos (AM), que debieran 
aparecer en los prospectos de medicinas, para el conocimiento de los pacientes y la prescripción de medicamentos, indicando 
sus efectos adversos fatales para el cuerpo humano. El objetivo de este estudio es averiguar el conocimiento de estudiantes de 
medicina y de farmacia sobre AM. Se entregó un cuestionario con contenidos sobre AM a estudiantes de farmacia y de medi-
cina de primero a tercer año de diferentes institutos médicos y farmacéuticos. Se obtuvo un 76% de respuesta. Se observó que 
el conocimiento de los estudiantes sobre AM mejora asociado a la promoción en años profesionales de medicina y farmacia. 
Los resultados indican que el conocimiento de los estudiantes sobre alerta de medicamentos aumenta con el nivel de estudio. 
Debería implementarse la formación sobre alerta de medicamentos en farmacia y medicina y ayudar a los estudiantes a tener 
conocimiento actual sobre alerta de medicamentos de forma que, en el futuro, puedan realizar prácticas éticas en sus campos 
respectivos.
Palabras clave: efectos secundarios, Agencia Reguladora de Alimentos y Medicamentos, formación, cuestionarios basados 
en encuestas
Uma avaliação sobre o acesso de estudantes paquistaneses de medicina e farmácia ao 
conhecimento das advertências das caixas de tarja preta
Resumo: A Food and Drug Administration disponibiliza as advertências das caixas de tarja preta (BBW) que devem aparecer 
em bulas de medicamentos para  conscientização de pacientes e a prescrição de drogas, indicando seus efeitos adversos alta-
mente fatais para o corpo humano. O propósito deste estudo foi o de de inteirar a cerca do conhecimento de estudantes de 
medicina e farmácia sobre BBW. Um questionário com conteúdos sobre BBW foi dado a estudantes de farmácia e medicina, 
do 1º, 2º e 3º ano de diferentes instituições de ensino em farmácia e medicina. Foi observada uma taxa de 76% de resposta 
dos pesquisados. Observou-se que o conhecimento de estudantes sobre BBW melhora quando se associa à promoção para 
anos seguintes da educação nas faculdades de farmácia e medicina. Os resultados indicam que o conhecimento dos estudantes 
sobre as caixas de tarja preta aumenta com o nível de estudo. Treinamento com caixas de tarja preta pode ser implementado 
em instituições de ensino de farmácia e medicina, influenciando de modo significativo as formas de educação e treinamento 
de estudantes de farmácia e medicina, e, assim, ajudar estes estudantes a obter conhecimentos recentes sobre medicamentos de 
tarja preta de modo que, no futuro, elas possam exercer uma prática ética em seus respectivos campos de atuação profissional. 
Palavras-chave: efeitos colaterais, Food and Drug Administration, treinamento, pesquisa baseada em questionário
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Introduction
Black box warnings (BBW) appear on the leaflets 
of medicines indicating its serious adverse effects 
for patient awareness(1). The BBW are delivered 
by FDA (Food and Drug Administration) for the 
prescription of drugs having highly fatal adverse 
effects to the body(2). The Adverse Event Repor-
ting System and the Office of Surveillance and 
Epidemiology evaluate post-market safety obser-
vations and identify these safety concerns. The 
most widespread category of warning is released 
on observing a potentially severe unfavorable 
effect that must be vigilantly pondered against 
the potential advantage of the drug(3). The BBW 
are also released to attract attention to potential 
drug interactions, dosing and monitoring requi-
sites. The BBW have recently been released for 
fluoroquinolones, oral sodium phosphate bowel 
preparations and salmeterol. Regardless of these 
extremely revealed BBW, all of these medications 
remain practical treatment choices with apposite 
patient assortment. Eventually, physicians must 
make a decision whether to prescribe drugs ha-
ving boxed warnings(4-7). The BBW are impo-
sed to the drugs which have been approved for 
marketing which include life threatening infor-
mation(5).
Many black box warnings are collected by post-
marketing surveillance, rather than controlled 
clinical trials(6). Newly approved drugs may ex-
hibit more unrecognized adverse drug reactions 
as compared to the established drugs(7). The 
complete description, estimate risk and a conclu-
sion of suspected effects by the harmful reactions 
and other risk factors like dose, sex, contraindi-
cations, age and duration of use is mentioned 
on the drugs leaflets having black box warnings. 
The pharmaceutical companies are required to 
reproduce black box warnings on the labeling 
or in the literature of the respective drugs. The 
informations about the restrictions of highly to-
xic drugs may also be included in the black box 
warnings. The total number of drugs having black 
box warnings is approximately 350(8-11). Due to 
the observations from other class members of the 
drug or because of the animal studies, the chan-
ces of an adverse reaction by a medicine can be 
expected(9,13). Some black box warnings suggest 
against simultaneous administration of particular 
medicines attributable to an enlarged jeopardy 
for life-threatening effects.
In Pakistan, the black box was opened on Ja-
nuary 1, 2005 and adopted FDA rules of black 
box warnings in Pakistan. The products in black 
box are processed under the developed rules(14). 
Healthcare providers like pharmacists are often 
not well-informed about the source, significance, 
and insinuations of these black box warnings. In 
this context, present study was designed to as-
sess the knowledge of black box warnings among 
pharmacy and medical students of six institutes 
in Pakistan.
Methodology
Study design: The investigation about black box 
warnings among pharmacy and medical students 
was completed through cross-sectional study de-
sign. The basic purpose behind is survey is to es-
tablish knowledge among pharmacy and medical 
students and to check their current knowledge re-
garding to black box warnings. Data were assem-
bled by questionnaires and through face-to-face 
interview. The survey was assessed by the com-
bined efforts of faculty members and students of 
COMSATS Institute of Information Technolo-
gy, Abbottabad. This study was approved by the 
Board of Advanced Studies and Research (Local 
Ethical Committee), COMSATS Institute of In-
formation Technology, Abbottabad, Pakistan.
Study location: Six institutes in Pakistan [CIIT 
(COMSATS Institute of Information Technolo-
gy), Hazara University (HU), PIPS (Pakistan Ins-
titute of Professional Studies), WIL (Women Ins-
titute of Learning) AMC (Ayub Medical College) 
and FMC (Frontier Medical College) were selec-
ted as research-rigorous organizations. The survey 
was conducted from undergraduate pharmacy 
and medical students. A two stage random sam-
pling methodology was employed. During stage 
1, students were selected through simple random 
sampling and stage 2 covered the assortment of 
students from other locations. The students were 
briefed the aim of study and then obtained sanc-
tion from the students to participate in this study. 
The filling of questionnaires was conducted in the 
presence of an expert researcher for assisting the 
respondents, if required.
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Data collection: This survey was conducted using 
a structured pre-channeled questionnaire contai-
ning 28 different closed-ended and open-ended 
questions. The questionnaire contained questions 
on demography and students’ knowledge about 
BBW of various medications. The questions on 
selected brand and generic medications (having 
a wide range of indications) corresponded to 
various factors like: (vi) medications with and 
without advertisement about the addition of 
black box warnings or severe undesirable outco-
mes, (iv) over the counter and prescription-only 
medications, (ii) frequency of use in clinical prac-
tice, and (v) the period of marketing. Based on 
Cohen’s Kappa points for inter-annotator, the 
responses to open-ended questions were reviewed 
by two experts, who classified the responses with 
mutual harmony as correct or incorrect. Five 
questions covered the general knowledge about 
black box warnings, while 23 questions were as-
ked about drugs having black box warnings. De-
mographic informations consisted of age, sex and 
year of their studentship. The respondents were 
also permitted to add any additional information 
regarding their knowledge about BBW. After pi-
lot-testing for content and design on 25 students, 
necessary modifications were made in the ques-
tionnaire. The students were not allowed to use 
any helping material and discussion among each 
other. A complete examination environment for 
15-20 min was provided to the students so that 
their personal knowledge about black box war-
nings could be assessed(4).
Data analysis: Data was analyzed using SPSS ver-
sion 13.0 with confidence interval of 95%.
Results and discussion
Firstly, it was checked that either students know 
“what are black box warnings” in response we ob-
served that mean percentage of 69%, 80% and 
83% from 1st, 2nd and 3rd professional year phar-
macy and medical students responded positively. 
Then, the activity was further continued by as-
king different types of medicines with their BBW 
using multiple choice questions. About 76% stu-
dents answered positively.
Different medications with BBW and the res-
ponse strength of 1st PYPS (professional year 
pharmacy students) are shown in Figure 1. The 
1st PYPS have least knowledge about medicines 
with BBW having nominal familiarity about 
some common medicine’s BBW like paracetamol 
(8%), diclofenac sodium (7%), flagyl (7%) and 
alprostadil (4%), respectively.
The observed survey response rate was 76% (4256 
of 5600 students) with 1st PYPS = 590 (Number 
of respondent from 1st PYPS)/1095 (Total num-
ber of 1st PYPS), 2nd PYPS = 729/972, 3rd PYPS = 
361/400 and 1st PYMS (professional year medical 
students) = 297/718, 2nd PYMS = 268/567 and 
3rd PYMS = 418/509. The remaining students did 
not complete the questionnaires.
It was observed that the ability of pharmacy stu-
dents to answer about BBW in a list of 23 me-
dicines increased in association with curriculum/
professional year. Third PYPS have a significant 
knowledge about black box drugs than first pro-
fessional year students. Pharmacy students who 
responded correctly about black box warnings 
were as: 1st PYPS = 53.88%, 2nd PYPS = 75.00% 
and 3rd PYPS = 88.03%). Black box warning con-
tent for alprostadil (1st PYPS = 3%, 2nd PYPS = 
1%), rosiglitazone (1st PYPS = 1%, 2nd PYPS = 
5%, 3rd PYPS = 30%) and stavudine (1st PYPS = 
2%, 2nd PYPS = 5%, 3rd PYPS = 30%) etc., were 
least known by the students however BBW con-
tent for paracetamol (1st PYPS = 55%, 2nd PYPS = 
88%, 3rd PYPS = 98%), metronidazole (1st PYPS 
= 54%, 2nd PYPS = 83%, and 3rd PYPS = 95%) 
and oxytocin (1st PYPS = 52%, 2nd PYPS = 48%, 
and 3rd PYPS = 98%) were also known by the stu-
dents as good as given in above data.
Table 1: Results obtained from the medical and 
pharmacy students about black box warnings
1st 
Professional 
Year
2nd 
Professional 
Year
3rd 
Professional 
Year
Medical 41.36% 46.52% 82.82%
Pharmacy 53.88% 75% 88.03%
 
Different medications and the responses from the 
3rd PYPS are shown in Figure 1. Knowledge of 
2nd PYPS about black box medication was qui-
te better than 1st PYPS. The whole percentage of 
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2nd PYPS was 76% regarding the knowledge of 
black box medications. More then 90% knowled-
ge of 2nd PYPS was familiar about BBW of para-
cetamol, flagyl, diclofenac sodium and oxytocin. 
The least knowledge of 2nd PYPS about BBW 
was about amoxapine (30%), adefovir dipivoxil 
(15%), cisplastin (14%), lefnonoide (15%) and 
hydoxyurea (21%), respectively.
Different medications and the responses from the 
2nd PYPS are shown in Figure 1. In this survey, the 
most correct results were observed by 3rd PYPS. 
They possessed knowledge of majority of the me-
dicines with BBW. The 84% of 3rd PYPS correctly 
answered about captopril, estradiol, flagyl, oxyto-
cin and paracetamol as medicines having BBW. 
The 3rd PYPS (50%) had least knowledge about 
the BBW for amphetamine, ganeiclovir (Na), le-
flunonoide and hydoxyurea.
Figure 1: The percentage of 1st, 2nd and 3rd profes-
sional year pharmacy student’s (PYPS) and 1st, 2nd 
and 3rd professional year medical student’s (PYMS) 
knowledge about 11 black box medications.
 
Figure 1 exhibit medical students’ knowledge 
about BBW of medicines showing an increase in 
their knowledge with the seniority of professio-
nal year like pharmacy students. Like pharmacy 
students, some common medications with BBW 
were much known to 1st PYMS students i.e. pa-
racetamol, diclofenac sodium, metronidazole and 
oxytocin.
Medical students who responded correctly about 
black box warnings were as: 1st PYMS = 41.36%, 
2nd PYMS = 46.52% and 3rd PYMS = 82.82%). 
Table 1 shows that 1st PYMS (professional year 
medical students) possess significantly (p<0.05) 
lesser knowledge as compared to that of 1st pro-
fessional year pharmacy students perhaps it is be-
cause of that pharmacy students’ interaction with 
pharmacology discipline is more than that of me-
dical students. Same result was also seen in 2nd 
and 3rd PYMS.
Figure 2: Percentage of students from different insti-
tutions possessing good knowledge about black box 
warnings.
 
Figure 2 indicates that the number of students 
possessing sufficiently good knowledge about 
BBW from CIIT, HU, WIL, AMC, PIPS and 
FMC are 739/920 (80.32%), 451/704 (64.06%), 
300/472 (61.86%), 676/1178 (57.38%), 
198/371 (53.36%) and 307/611 (50.20%), res-
pectively. Among the six institutions, the students 
of CIIT showed significantly (p<0.05) better 
knowledge about BBW, as black box warnings are 
not potentially taught in the other five institu-
tions, it may be due to the lack of highly qualified 
faculty and less frequency of seminars, worshops 
and conferences in those five institutes.
The knowledge of black box warnings among 
pharmacy and medical students improves as the 
educational year progresses(5). Before survey, 
it was expected that the knowledge of students 
about black box warnings will be significantly 
less, as in Pakistan, pharmacy education and its 
practice is not as mature as in developed coun-
tries but the results were highly impressive when 
we observed the data obtained as a result of this 
survey.
The 1st professional year students response about 
BBW was not satisfactory as their knowledge was 
very less because they do not study about drugs 
in their first year course plan. While 2nd and 3rd 
professional year students’ response rate was im-
pressive. Some common drugs having BBW were 
much known to many of the students of 1st pro-
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fessional year like paracetamol and metronidazole 
but they could not justify their answers logically. 
On contrary, 2nd professional year students’ res-
ponse to drugs like paracetamol, flagyl, oxytocin, 
estradiol and captopril was very effective as most 
of the 2nd professional year students knew about 
exact reason of BBW for above mentioned drugs. 
The 3rd professional year students, the most senior 
students of our survey responded very well like 
2nd professional year students, as their response 
was reasonably correct for BBW of majority of 
the drugs. Some drugs like paroxetine, metha-
done, oxytocin, paracetamol, metronidazole, di-
clofenac acid, alprostadil and losartin were much 
known to them. 
A previous study elaborated that a large num-
ber of pharmacy students mentioned here do 
not stay updated with the latest issues of black 
box warnings. However, provision of data to the 
pharmacists and medical prescribes does not in-
fluence their behavior of prescription(12). The-
re are many sources for informations regarding 
BBW like FDA website(7). At present, the study 
of BBW may be conducted under the umbrella 
theme of medication safety in the pharmacy and 
medical institutes, accompanied by a proper trai-
ning to the students in this crucial area.
Limitations of study
Further studies are required for the identification 
of the students’ knowledge about black box war-
nings. This survey was conducted only at six ins-
titutions which was a limitation of this study. The 
inclusion of other institutions in such study may 
produce different results as a result of an extensi-
ve survey. Awareness among the pharmacists and 
medical practioners about black box warnings 
should also be determined. Another limitation is 
that this survey instrument was not validated.
Conclusion
This survey about black box warnings conducted 
in 1st, 2nd and 3rd professional year pharmacy and 
medical students shows that student’s understan-
ding and awareness of black box warnings impro-
ves with their professional year advancement. Tra-
ining in black box warnings should be implemen-
ted in pharmacy and medical institutions influen-
cing the meaningful ways to educate and train 
pharmacy and medical students, and help these 
students to get recent knowledge about black box 
warnings so that, in future, they may perform an 
ethical practice in their respective fields.
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